APOE4-to-APOE2 Gene Editing — Gene Therapy & Genetic Interventions
CRISPR base editing to convert the Alzheimer's risk allele APOE4 to the protective APOE2 variant.
Overview
APOE4 is the strongest genetic risk factor for late-onset Alzheimer's disease, carried by ~25% of the population. APOE4 homozygotes have a 10-15x increased risk. APOE2 is protective, associated with reduced amyloid burden and extended lifespan. CRISPR adenine base editing can convert APOE4 (Arg112, Arg158) to APOE2 (Cys112, Cys158) via single-nucleotide changes without double-strand DNA breaks. Preclinical studies in iPSC-derived neurons and mouse models demonstrate feasibility, with correction of lipid metabolism and reduced tau phosphorylation.
Indications
- Alzheimer's disease risk reduction (APOE4 carriers)
- Cerebral amyloid angiopathy prevention
- Cardiovascular risk reduction (APOE4-associated dyslipidemia)
- Longevity optimization in APOE4 carriers
Mechanism of Action
AAV or LNP delivers adenine base editor (ABE) complexed with guide RNA targeting APOE4 SNPs
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| AAV-ABE (adenine base editor) | Study-specific | Single intrathecal or IV infusion | CNS-tropic AAV serotype (AAV9/AAVrh10) required |
| LNP-delivered ABE mRNA | Study-specific | Single or repeated infusion | Non-viral delivery under investigation |
Evidence Grade
GRADE C
Safety & Contraindications
- Off-target base editing at unintended genomic loci
- Bystander editing of nearby nucleotides within the editing window
- Delivery to sufficient CNS neurons remains a major technical challenge
- Immunogenicity of Cas9 protein and AAV vector
- Mosaicism: incomplete editing may result in mixed APOE genotypes
- No human clinical trials initiated